Sight Sciences, Inc. SGHT

Annual Quarterly

Q3 FY2026 · ended Sep 30, 2026 · Revenue $24.92M, +25.2% YoY · Filed Nov 4, 2026

Sight Sciences, Inc. (SGHT) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $24.9 million and a net loss of $6.8 million. Free cash flow was -$2.5 million. As of Sep 30, 2026 it held $77.4 million in cash and investments and $48.2 million in total debt.

Revenue
$24.92M
+25.2% vs year-ago quarter
Net income
$-6.81M
+16.6% vs year-ago quarter
Operating cash flow
$-2.40M
+72.5% vs year-ago quarter
Free cash flow
$-2.47M
+72.2% vs year-ago quarter
EPS
$-0.12
+25.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
55.58M
+5.1% vs year-ago quarter
Net cash
$29.23M
Q3 FY2026
Operating margin
-29.5%
TTM

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
SGHT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Menlo Park, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1531177

Other Surgical & Medical Instruments & Apparatus companies

All 151 Surgical & Medical Instruments & Apparatus companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Revenue
$24.9M
$23.4M
$19.7M
$20.4M
$19.9M
Operating income
-$6.1M
-$3.9M
-$12.4M
-$3.7M
-$7.9M
Net income
-$6.8M
-$4.4M
-$13.0M
-$4.2M
-$8.2M
Diluted EPS
-$0.12
-$0.08
-$0.24
-$0.08
-$0.16
Operating cash flow
-$2.4M
-$5.7M
-$7.0M
-$1.8M
-$8.7M
Free cash flow
-$2.5M
-$5.7M
-$7.1M
-$2.0M
-$8.9M
Total assets
$104.9M
$104.9M
$109.7M
$115.3M
$116.3M
Total liabilities
$55.8M
$52.0M
$55.8M
$51.4M
$52.0M
Stockholders' equity
$49.1M
$52.9M
$53.9M
$63.9M
$64.3M
Cash and investments
$77.4M
$79.8M
$85.0M
$92.0M
$92.4M
Total debt
$48.2M
$52.1M
$45.6M
$40.8M
$40.7M

Recent SEC filings

Form Description Filed Period
10-Q Quarterly report Nov 4, 2026 Sep 30, 2026
8-K Current report
Results of operations, Regulation FD disclosure
 Nov 4, 2026 Nov 4, 2026
8-K Current report
Officer or director change
 Aug 10, 2026 Aug 6, 2026
10-Q Quarterly report Aug 5, 2026 Jun 30, 2026
8-K Current report
Results of operations, Regulation FD disclosure
 Aug 5, 2026 Aug 5, 2026
8-K Current report
Shareholder vote results
 Jun 5, 2026 Jun 4, 2026

All 508 Sight Sciences, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.